MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status

W. D. Foulkes, G. W.H. Stamp, S. Afzal, N. Lalani, C. P. McFarlane, J. Trowsdale, I. G. Campbell

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)


Somatic mutations in TP53 are seen in many human cancers. In addition, the protein product of the wild-type TP53 can be sequestered by the protein MDM2 (murine double minute 2). This protein is commonly overexpressed in human sarcomas and gliomas, usually as a result of gene amplification. In this study, 43 ovarian carcinomas (OCs) were analysed for aberrations in the TP53 gene by immunohistochemistry (IHC), loss of heterozygosity (LOH) or mutation analysis. The MDM2 gene and its product was studied by Southern blotting and IHC. Over 50% of the OCs studied showed mutations in TP53 by either direct sequencing (19/36, 53%), positive IHC (23, 43, 53%) or both, whereas 0/32 had amplification of MDM2 and only 1/37 tumours had positive IHC using the anti-MDM2 antibody IF-2. The solitary example of positive IHC in this series was seen in a mixed müllerian tumour with sarcomatous differentiation and was not accompanied by MDM2 DNA amplification. These results support previous data showing that around 50% of OCs have mutations in TP53 and in addition, suggest that MDM2 is not amplified in OC, but the presence of sarcomatous features in mixed müllerian tumours may result in positive immunohistochemistry with IF-2.

Original languageEnglish
Pages (from-to)883-888
Number of pages6
JournalBritish Journal of Cancer
Issue number4
Publication statusPublished - Oct 1995
Externally publishedYes


  • Immunohistochemistry
  • Mdm2
  • Mutation
  • Ovarian cancer
  • Tp53


Dive into the research topics of 'MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status'. Together they form a unique fingerprint.

Cite this